AtriCure, Inc.

271 articles with AtriCure, Inc.

• AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2020

  1/11/2021

  AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced preliminary financial results for the fourth quarter and full year 2020.

• AtriCure Announces Labeling Expansion for Cryo Nerve Block Therapy

  1/4/2021

  Expansion includes adolescent patients, as young as 12 years of age, who can benefit from cryo nerve block therapy during surgical procedures involving the chest wall.

• AtriCure to Participate in the 39th Annual J.P. Morgan Healthcare Conference

  12/14/2020

  AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming 39th Annual J.P. Morgan Healthcare Conference being held virtually.

• AtriCure to Participate in Upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference

  11/19/2020

  AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will participate in the upcoming Piper Sandler 32 nd Annual Virtual Healthcare Conference. Conference Dates: Tuesday, December 1 to Thursday

• AtriCure Reports Third Quarter 2020 Financial Results

  11/5/2020

  AtriCure, Inc., a leading innovator in treatments for atrial fibrillation and left atrial appendage management, announced third quarter 2020 financial results.

• AtriCure to Participate in Upcoming Investor Conferences - Oct 26, 2020

  10/26/2020

  AtriCure, Inc., a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, announced that the company will be participating in two upcoming investor conferences.

• AtriCure to Announce Third Quarter 2020 Financial Results

  10/13/2020

  AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2020 financial results on Thursday, November 5, 2020. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, November 5, 2020 to discuss its third quarter 2020 financial results. The call may be accessed

• AtriCure to Participate at the Morgan Stanley 18th Annual Global Healthcare Conference

  9/1/2020

  AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Morgan Stanley 18 th Annual Global Healthcare Conference being held virtually. AtriCure’s management is scheduled to pr

• AtriCure to Participate at Upcoming Investor Conferences

  7/29/2020

  AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in several upcoming investor conferences. AtriCure will be participating in the Guggenheim MedTech Disruptors Summit, scheduled to be held virtually August 10-11, 2020. AtriCure’s management is scheduled to present

• AtriCure Reports Second Quarter 2020 Financial Results

  7/28/2020

  AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2020 financial results.

• AtriCure to Announce Second Quarter 2020 Financial Results

  7/7/2020

  AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2020 financial results on Tuesday, July 28, 2020. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, July 28, 2020 to discuss its second quarter 2020 financial results. The call may be accessed throug

• AtriCure Announces Pricing of Public Offering of Common Stock - May 12, 2020

  5/12/2020

  AtriCure, Inc., a leading innovator in treatments for atrial fibrillation and left atrial appendage management, announced the pricing of its underwritten offering of 3,977,273 shares of its common stock at a price to the public of $44.00 per share pursuant to its existing automatic shelf registration statement.

• AtriCure Announces Proposed Public Offering of Common Stock - May 11, 2020

  5/11/2020

  AtriCure, Inc. announced it has commenced a proposed underwritten public offering in which it expects to issue and sell approximately $100 million of shares of its common stock pursuant to its existing automatic shelf registration statement.

• AtriCure Announces Results from CONVERGE IDE Clinical Trial

  5/8/2020

  Results presented virtually via Heart Rhythm 365 Platform; study met primary effectiveness endpoint of superiority in favor of the hybrid Convergent procedure MASON, Ohio--( BUSINESS WIRE )-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the results from the CONVERGE IDE clinical trial. This first-of-its-kind trial, designed to demonstrate supe

• AtriCure Announces Investor Update Webcast on May 8, 2020 in Conjunction with the 41st Annual Heart Rhythm Society (HRS) Virtual Meeting

  4/30/2020

  AtriCure Announces Investor Update Webcast on May 8, 2020 in Conjunction with the 41 st Annual Heart Rhythm Society (HRS) Virtual Meeting

• AtriCure Reports First Quarter 2020 Financial Results

  4/29/2020

  AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced first quarter 2020 financial results.

• AtriCure to Participate at Upcoming Investor Conferences in May 12, 2020

  4/27/2020

  AtriCure, Inc., a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, announced that the company will be participating in two upcoming investor conferences.

• AtriCure to Announce First Quarter 2020 Financial Results

  4/15/2020

  AtriCure, Inc. today announced that it will release its first quarter 2020 financial results on Wednesday, April 29, 2020. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Wednesday, April 29, 2020 to discuss its first quarter 2020 financial results. The call may be accessed

• AtriCure Announces CONVERGE IDE Trial Results Accepted for Late-Breaking Clinical Trial Sessions at Annual Heart Rhythm Society (HRS) Meeting

  4/13/2020

  AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that results from the CONVERGE IDE trial have been accepted for presentation in the late-breaking abstract sessions at the Heart Rhythm Society (HRS) Scientific Sessions. The abstract will be presented as a webinar on Heart Rhythm 365, the society’s digital informati

• AtriCure Announces Preliminary Financial Results for First Quarter 2020 and Provides COVID-19 Pandemic Update

  4/9/2020

  AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the first quarter 2020 and provided updates in response to the COVID-19 pandemic.